BMX-001 is under clinical development by Biomimetix JV and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BMX-001’s likelihood of approval (LoA) and phase transition for High-Grade Glioma took place on 22 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BMX-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BMX-001 overview

BMX-001 is under development for the treatment of allergic dermatitis, anal squamous cell carcinoma, rectal adenocarcinoma (RAC), high-grade gliomas, reperfusion injury, squamous cell carcinoma of head and neck cancer including oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, oral cavity cancer and metastatic brain tumor. It is administered by subcutaneous and topical route. BMX-001 is a Mn(III) N-substituted pyridylporphyrin (MnP)-based SOD mimic.

Biomimetix JV overview

Biomimetix JV (Biomimetix) develops a new class of redox active metalloporphyrin compounds for the treatment of inflammatory skin disease and cancer patients undergoing radiation therapy and chemotherapy. Its pipeline products include BMX-001 targeting high-grade glioma, head and neck cancers, brain metastases, and anal cancer and BMX-010 indicated for the treatment of atopic dermatitis, pruritus (itch), acne, psoriasis, rosacea, and other chronic inflammatory skin conditions. Biomimetix’s compounds modulates key nuclear transcription factors to inhibit inflammatory pathways and also stimulating the production of antioxidants. Biomimetix is headquartered in Greenwood Village, Colorado, the US.

Quick View BMX-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • BMX-001
Administration Pathway
  • Subcutaneous
  • Topical
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.